Gan & Lee Pharmaceuticals.
SSE:603087.SS
55.83 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||||
| Net Income
| 614.664 | 340.069 | -439.516 | 1,452.755 | 1,230.711 | 1,167.281 | 933.965 | 1,079.954 | 769.632 | 447.423 | 305.217 | 204.726 |
| Depreciation & Amortization
| 257.455 | 225.259 | 200.345 | 184.877 | 159.596 | 115.832 | 91.174 | 50.981 | 0.013 | 4.675 | 4.632 | 4.082 |
| Deferred Income Tax
| 0 | 0 | -143.596 | -11.508 | -9.059 | 20.132 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 0 | 0 | 19.593 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Working Capital
| -136.946 | -373.377 | 498.762 | -355.546 | -134.778 | -62.886 | -604.215 | -173.114 | 0 | 0 | 0 | 0 |
| Accounts Receivables
| 132.153 | 480.758 | 2,224.078 | -155.183 | -8.713 | -87.657 | -544.65 | -102.69 | 0 | 0 | 0 | 0 |
| Inventory
| -203.04 | -239.143 | -35.444 | -158.466 | -25.3 | -98.602 | -176.017 | -72.717 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 0 | -665.104 | -1,546.277 | -30.389 | -91.707 | 100.224 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital
| -66.06 | 50.112 | -143.596 | -11.508 | -9.059 | 23.149 | -428.198 | -100.397 | 0 | 0 | 0 | 0 |
| Other Non Cash Items
| -197.862 | 235.737 | 161.094 | -203.909 | -14.186 | -66.296 | -2.887 | -8.222 | -769.632 | -447.423 | -305.217 | -204.726 |
| Operating Cash Flow
| 537.31 | 427.688 | 296.682 | 1,078.176 | 1,241.343 | 1,153.931 | 418.038 | 949.599 | 769.632 | 447.423 | 305.217 | 204.726 |
| Investing Activities: | ||||||||||||
| Investments In Property Plant And Equipment
| -440.801 | -553.058 | -983.444 | -692.083 | -582.143 | -406.633 | -513.441 | -431.024 | -258.48 | -368.434 | -315.47 | -100.064 |
| Acquisitions Net
| 0 | 0 | 0.06 | 1.017 | 0.856 | 0.355 | 12.918 | 0.077 | -0 | 0.071 | 0.036 | 0.007 |
| Purchases Of Investments
| -8,679.035 | -7,999.322 | -4,294.988 | -2,991.289 | -9,596.13 | -5,744.3 | -4,122 | -3,539.9 | -1,710.79 | -2,645.5 | -3,381.58 | -3,116.6 |
| Sales Maturities Of Investments
| 8,855.204 | 7,573.082 | 4,803.261 | 3,222.698 | 6,960.754 | 4,945.307 | 3,985.045 | 3,237.213 | 1,341.761 | 2,303.29 | 3,392.401 | 3,153.328 |
| Other Investing Activites
| 2.604 | -316.335 | 32.665 | -38.477 | -6.265 | 30.013 | -53.457 | 7.634 | 34.497 | 30.511 | -33.17 | 0.08 |
| Investing Cash Flow
| -262.028 | -1,295.633 | -442.446 | -498.135 | -3,222.928 | -1,175.259 | -690.935 | -726 | -593.012 | -680.062 | -337.783 | -63.25 |
| Financing Activities: | ||||||||||||
| Debt Repayment
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -29.7 | -36.795 | 43.792 | 17.028 | -2 |
| Common Stock Issued
| 0 | 759.728 | 71.364 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| -420.547 | 0 | -168.462 | -224.616 | -200.55 | 0 | 0 | -1.733 | -2.27 | -2.791 | -0.283 | -26.214 |
| Other Financing Activities
| 119.833 | 754.699 | -3.772 | -4.316 | 2,441.134 | 3.676 | 0 | -1.733 | 0 | 18.528 | -18.528 | 0 |
| Financing Cash Flow
| -300.714 | 754.699 | -100.87 | -228.932 | 2,240.584 | 3.676 | 0 | -31.433 | -39.065 | 59.529 | -1.783 | -28.214 |
| Other Information: | ||||||||||||
| Effect Of Forex Changes On Cash
| -0.951 | 2.357 | 4.195 | -2.677 | -0.881 | 4.499 | 1.954 | -2.251 | 1.03 | 1.94 | -8.796 | -37.631 |
| Net Change In Cash
| -26.384 | -110.89 | -242.439 | 348.433 | 258.118 | -13.153 | -270.944 | 189.915 | 55.092 | -116.12 | -43.145 | 75.632 |
| Cash At End Of Period
| 260.055 | 286.439 | 397.329 | 639.768 | 291.335 | 33.217 | 46.37 | 317.314 | 127.398 | 72.307 | 188.427 | 231.572 |